Mizuho Maintains Outperform on ResMed, Lowers Price Target to $220

Benzinga Newsdesk www.benzinga.com Negative 94.9%

Neg 94.9% Neu 0% Pos 0%

Mizuho analyst Anthony Petrone maintains ResMed (NYSE:RMD) with a Outperform and lowers the price target from $235 to $220.